MedTrace Logo

A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects

NCT06905327 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2025-12-04

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled study including Part A single ascending dose (SAD) in healthy subjects and Part B single dose in subjects with mild hypertension.

Conditions

  • Mild Hypertension

Interventions

DRUG

QCZ484

doses of 50, 150, 300 or 600 mg via subcutaneous injection

DRUG

Placebo

via subcutaneous injection

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-08
Primary Completion
2024-09-25
Completion
2025-07-01
FDA Drug
Yes

Countries

  • Australia
  • New Zealand

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06905327 on ClinicalTrials.gov